Mon, 20th Aug 2012 07:43
* Fatal brain-wasting disease has no effective treatments * Experts say drug failures may be due to late trials * Predictive test could find people before disease sets in * Shares in Proteome Sciences, involved in work, jump 12 pct (Adds Proteome Sciences stock move) By
Read moreLONDON (Alliance News) - Proteome Sciences PLC Thursday expressed confidence for continued fast revenue growth for the "forseeable future", as it posted a narrowed pretax loss for 2013, driven by strong sales of its Tandem Mass Tag reagents and growth in its biomarker assays. Proteome is en
Read moreLONDON (Alliance News) - Proteome Sciences PLC said Thursday that a study using its SysQuant technology to address pancreatic cancer published in medical journal PLOS ONE demonstrated the potential of proteomics to improve the way that bespoke treatments can be made to match patients. Prote
Read moreXP Power's Chairman, Larry Tracey, on Thursday sold 75,000 shares in the power supply solutions manufacturer. Tracey, who has held his current role since April 2002, disposed of the shares at 1,755p a time, generating a total of £1.3m. Fellow board member James Peters, a Non-Executive Director, t
Read moreLONDON (Alliance News) - Proteome Sciences PLC said Monday it has placed 17.9 million new shares on the market to raise GBP5 million before expenses, with new and existing investors, which it will use for additional working capital. The protein biomarker company said the shares were placed
Read moreBiotech group Proteome Sciences edged ahead after it revealed it expects revenue for 2013 to show "a significant increase" over 2012 thanks to strong performance across its core activities. The firm is an expert in biomarkers, or biological markers, that can help predict the likelihood of cancer r
Read moreLONDON (Alliance News) - Shares in Proteome Sciences PLC rose in early trading Friday, after the protein biomarker company said revenue for 2013 will be significantly higher than the prior year, driven by a strong performance from all its core activities. Proteome is engaged in research an
Read moreBiotechnology group Proteome Sciences is facing sales delays that will push revenue from some deals into next year, hitting its shares. Proteome, which carries out research into protein and peptide biomarkers to treat neurological conditions and other illnesses such as cancer, said the timing and r
Read more